Recent 8-K filings for SBFM

• July 10, 2026, 4:54 PM ET litigation materiality 0.60 neutral item 1.01item 9.01

  Sunshine Biopharma settles dispute with former Nora Pharma president for CAD$1.5M

  Company to pay CAD$1.5M (approx US$1.06M) to Malek Chamoun to settle all claims and cross-claims.

• May 19, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Sunshine Biopharma Q1 revenue up 18% to $8.9M; net loss narrows

  Revenue of $8.9 million in Q1 2025, up 18% from $7.5M in Q1 2024.

• April 3, 2025, 7:59 PM ET other material materiality 0.60 positive item 1.01item 8.01item 9.01

  Sunshine Biopharma closes $2.46M registered direct offering of common stock and pre-funded warrants

  Gross proceeds of approximately $2.46M from sale of 1,188,404 shares of common stock (or pre-funded warrants) at $2.07 per share.

• April 2, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Sunshine Biopharma FY2024 revenue $34.9M (+45% YoY); net loss widens to $5.1M

  Revenue $34.9M in FY2024, up 45% from $24.1M in FY2023; gross profit $10.7M.

• November 7, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Sunshine Biopharma Q3 2024 revenues up 42% YoY; net loss widens 84% in quarter

  Q3 2024 gross revenues $8.44M, up 42% from $5.96M in Q3 2023; YTD revenues $25.28M, up 54%.

• July 1, 2024, 7:59 PM ET regulatory materiality 0.70 neutral item 8.01

  Sunshine Biopharma gets Nasdaq bid-price extension to Aug 26, 2024

  Received Nasdaq Hearings Panel exception until August 26, 2024 to regain minimum bid price compliance.

• June 7, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 3.01

  Nasdaq notifies Sunshine Biopharma of delisting due to warrant dilution

  Nasdaq staff determined to delist SBFM under Rule 5101 citing public interest concerns over Series A warrant cashless exercise provision.

• May 22, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Sunshine Biopharma Q1 2024 revenue up 54% to $7.54M; net loss narrows to $1.28M

  Q1 2024 revenue of $7,541,046, a 54% increase from $4,894,053 in Q1 2023.

• May 6, 2024, 7:59 PM ET other material materiality 0.65 negative item 4.01item 9.01 ◈ Auditor Changes

  Sunshine Biopharma dismisses auditor BF Borgers after SEC permanent ban

  BF Borgers CPA, PC was dismissed as independent auditor after SEC settled charges and permanently banned the firm.

• April 23, 2024, 7:59 PM ET other material materiality 0.60 neutral item 5.03item 9.01 ◈ Governance Changes

  Sunshine Biopharma effects 1-for-100 reverse stock split effective April 17, 2024

  1-for-100 reverse split of common stock (SBFM) and warrants (SBFMW) effective April 17, 2024.

• April 1, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Sunshine Biopharma reports 2023 sales $24.1M, loss per share improves to -$0.19

  Sales grew to $24,092,787 in 2023 from $4,345,603 in 2022; average quarter-over-quarter growth of 14%.

• March 6, 2024, 6:59 PM ET other material materiality 0.65 negative item 1.01item 3.02item 5.07 ◈ Shareholder Votes

  Sunshine Biopharma CEO buys voting-preferred shares for $10K; 1-for-200 reverse split approved

  CEO Steve Slilaty purchased 100,000 Series B Preferred shares for $10,000, each with 1,000 votes.

• March 1, 2024, 6:59 PM ET regulatory materiality 0.90 negative item 3.01 ◈ Listing & Compliance Notices

  Sunshine Biopharma receives Nasdaq delisting notice; stock at $0.10 or less for 10 days

  Nasdaq staff determined common stock bid price <= $0.10 for ten consecutive days as of Feb 27, 2024.

• February 15, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Sunshine Biopharma closes ~$10M underwritten public offering of units with warrants

  71,428,571 Units priced at $0.14/Common Unit and $0.139/Pre-Funded Unit; gross proceeds ~$10.0M.

• February 12, 2024, 6:59 PM ET other material materiality 0.65 positive item 1.01item 9.01

  Sunshine Biopharma repurchases and cancels warrants for ~21.6M shares for $3.14M total

  Bought back May 2023 warrants for 11,904,762 shares from Armistice Capital for $2,361,596; warrants cancelled.

• December 7, 2023, 6:59 PM ET other material materiality 0.60 neutral item 5.07 ◈ Shareholder Votes ×6

  Sunshine Biopharma annual meeting: directors elected, reverse split up to 1:40 approved

  All five director nominees elected with >16M votes each; broker non-votes 5.04M.

• November 13, 2023, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Sunshine Biopharma Q3 2023 revenues surge to $5.96M on Nora Pharma acquisition; net loss narrows to $0.04/sh

  Gross revenues $5,957,668 for Q3 2023, up from $132,808 a year earlier, driven by Nora Pharma Inc. acquisition.

• November 2, 2023, 7:59 PM ET other material materiality 0.70 negative item 1.02 ◈ Material Agreements

  Sunshine Biopharma terminates Adva-27a research agreement with JGH after unfavorable lab results

  Termination of Research Agreement with Jewish General Hospital effective Dec 2, 2023.

• October 20, 2023, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 9.01 ◈ Material Agreements

  Sunshine Biopharma amends warrants to $0.11 exercise price and removes CEO voting restriction

  Reduces exercise price of outstanding Tradeable Warrants to $0.11; Pre-Funded Warrants to $0.001 per share.

• August 11, 2023, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  Sunshine Biopharma Q2 2023 revenues jump 3,600% YoY to $5.56M

  Revenues of $5,560,865 for Q2 2023, a 3,600% increase over Q2 2022.

• May 16, 2023, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements ×3

  Sunshine Biopharma closes $5M private placement, issues shares and warrants

  Issued 5,952,381 units at $0.84/unit; each unit = 1 share (or pre-funded warrant) + 2 warrants at $0.59 exercise price.

• May 11, 2023, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Sunshine Biopharma reports Q1 2023 revenues of $4.89M, up 2,100% YoY

  Gross revenues of $4,894,053 for Q1 2023, a 2,100% increase over Q1 2022, driven by Nora Pharma acquisition.

• March 24, 2023, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Sunshine Biopharma receives Nasdaq deficiency notice for bid price below $1.00

  Nasdaq notified SBFM on March 24, 2023, of bid price non-compliance under Rule 5550(a)(2).

• February 28, 2023, 6:59 PM ET other material materiality 0.65 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  Sunshine Biopharma signs exclusive worldwide license with U. Arizona for PLpro COVID-19 treatment

  License grants exclusive worldwide rights to PLpro protease inhibitors of SARS-CoV-2 (COVID-19).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.55 · Most common event other_material

12 positive 8 negative 30 neutral

source · SBFM on sec.gov